samedan logo
 
 
spacer
home > pmps > spring 2004 > pharmaceutical counterfeiting ?° predicting the future
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Pharmaceutical Counterfeiting ?° Predicting the Future

It is always difficult to predict the future; were it easy I would make a living from sitting at home playing the lottery. However, if we cannot accurately predict what is around the corner then we can make educated assessments of what is likely to happen. Investigating counterfeit pharmaceuticals is very much an intelligence-based pursuit. In the intelligence world, the analysis of patterns of activity and the following of trends are powerful weapons. Long-term studies of activity and the accurate analysis of information gleaned can be of great value, particularly when planning strategies to combat such activity. These skills can be transferred to the commercial world and specifically in this case to the pharmaceutical industry. Thus we are able, theoretically at least, to gain an insight into the aims of the counterfeiter.

There are massive threats associated with pharmaceutical counterfeiting. It should be borne in mind that this is a truly global activity, which is in many cases life threatening. Statistics show that there is a gradual and constant increase in pharmaceutical counterfeiting, and recent events reveal that this activity is no longer confined to less developed countries. In the UK, Western Europe and the US we are fortunate in that we have responsible and reactive monitoring and regulatory agencies, which respond rapidly to all cases of illegal pharmaceuticals.

However, it is becoming more of a problem in the Western world and we cannot afford to become complacent. Less developed countries are not so fortunate in that they have no efficient methods of detecting counterfeit pharmaceuticals and the agencies responsible are under-funded or prone to corruption. It is ironic that the countries which are least capable of fighting this battle are those with the greatest problems.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By John Allan, Director of Pharmaceutical Investigation Division at Carratu International Plc

John Allan is a qualified linguist in Russian, Polish, German and Arabic. He spent 24 years in military intelligence serving in Berlin, Cyprus, the UK and the Middle East. In 1991, he was awarded the British Empire Medal for his work during the Gulf War. He left the military in 1995 to join Carratu as an Investigator in their Corporate Division before moving to pharmaceutical investigations four years ago. Since entering this specialised area he has conducted and led hundreds of investigations into counterfeit pharmaceuticals, patent infringement of pharmaceutical products and other associated matters. In 2001, John joined the board of Carratu International Plc and continues to lead investigations into all areas of the pharmaceutical industry worldwide.
spacer
John Allan
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

First own Gerresheimer Autoinjector - Gerresheimer and Midas Pharma announce strategic partnership

– Gerresheimer’s first own IP autoinjector suitable for both small and large molecules enhances broad portfolio of solutions, medical devices and pharmaceutical primary packaging – First joint project of Gerresheimer and Midas Pharma: Development and marketing of new autoinjector – One-stop-shop for biotech and pharma customers Duesseldorf, November 08, 2021 – Gerresheimer acquired the IP of a new generation cartridge based autoinjector from Midas Pharma. This is the start of a strategic partnership. The joint project comprises the development and marketing of the new generation autoinjector.
More info >>

White Papers

e-tools enhance clinical trial performance

e-novex

In today’s ever-evolving medical business, technological changes require innovation to meet growing market demands and to bring about advances in the industry. One such development currently taking place in the field of clinical research is how e-tools are initiating a boost in the productivity of clinical trials.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement